Payment overview · 2025
General Payments
$170.86
10 reported records · 7 companies
Healthcare provider profile · identity verified
Abdelle Ferdinand Cheres, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · STREETSBORO, OH · NPI 1881949865
Verified facts
What the public records show
CMS Open Payments records show Abdelle Ferdinand Cheres, M.D. received $170.86 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 412 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.89 | 21.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$31.97 | 18.7% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $28.50 | 16.7% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $20.90 | 12.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.43 | 12.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.60 | 11.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.57 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.86 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
156 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
412 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
138 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
224 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 661 | 155 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 451 | 119 |
| Jardiance | Empagliflozin | 412 | 78 |
| Glimepiride | Glimepiride | 387 | 107 |
| Ozempic | Semaglutide | 372 | 62 |
| Metformin Hcl | Metformin Hcl | 361 | 104 |
| Farxiga | Dapagliflozin Propanediol | 246 | 52 |
| Trulicity | Dulaglutide | 224 | 39 |
| Humalog Kwikpen U-100 | Insulin Lispro | 223 | 61 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 213 | 66 |
| Pioglitazone Hcl | Pioglitazone Hcl | 171 | 40 |
| Synthroid | Levothyroxine Sodium | 156 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 54 |
| Metformin Hcl Er | Metformin Hcl | 144 | 48 |
| Mounjaro | Tirzepatide | 138 | 26 |
| Methimazole | Methimazole | 133 | 28 |
| Januvia | Sitagliptin Phosphate | 132 | 33 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 113 | 33 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 98 | 18 |
| Novolog Flexpen | Insulin Aspart | 92 | 37 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 80 | 27 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 77 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 75 | 18 |
| Glipizide | Glipizide | 73 | 20 |
| Lisinopril | Lisinopril | 70 | 16 |
| Gabapentin | Gabapentin | 69 | 15 |
| Hydrocortisone | Hydrocortisone | 67 | 14 |
| Humalog | Insulin Lispro | 61 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 14 |
| Rybelsus | Semaglutide | 59 | 13 |
| Insulin Lispro | Insulin Lispro | 57 | 13 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 54 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 54 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 53 | 16 |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 50 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 46 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 40 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 40 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 39 | suppressed |
| Admelog Solostar | Insulin Lispro | 38 | suppressed |
| Glipizide Er | Glipizide | 36 | 12 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | 13 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 30 | suppressed |
| Tirosint | Levothyroxine Sodium | 30 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Propylthiouracil | Propylthiouracil | 15 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 15 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Apidra Solostar | Insulin Glulisine | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 11 |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.86 · 10 records | ABBVIE INC. | Dexcom G6 Transmitter, GVOKE HYPOPEN, MINIMED 780G, MOUNJARO, TWIIST, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error